Evidence map›Paper›PMID 42064763›Full record

ArticleFrontiers in endocrinology2026

Integrated causal inference, kidney transcriptomics, and experimental validation identify ChREBP (

Mingliang Liu, Shihang Chen, Shi Wu, Bei Sun, Liming Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mingliang Liu *School of Medicine, Nankai University, Tianjin, China.
Shihang Chen *NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.
Shi Wu *NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.
Bei SunNHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.
Liming ChenSchool of Medicine, Nankai University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diabetic kidney disease (DKD) remains a leading cause of end-stage renal disease despite advances in glucose-, blood pressure-, and albuminuria-lowering therapies. The glucose-responsive transcription factor carbohydrate response element-binding protein (ChREBP; encoded by Methods: We integrated two-sample Mendelian randomization (MR), kidney transcriptomic stratification, network analyses, and experimental validation. MR used blood cis-eQTL instruments for Results: Genetically predicted higher Conclusions: Integrating genetic inference, confounding-aware kidney transcriptomics, network biology, and experimental validation, our study supports

Indexed as

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsDiabetes Mellitus, Type 2Diabetic NephropathiesKidneyTranscriptomeAnimalsGene Expression ProfilingHumansMaleMetabolic ReprogrammingMiceMice, Inbred C57BLBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsMLXIPL protein, humanMlxipl protein, mousealbuminuriaChREBPdiabetic kidney diseasemendelian randomizationmetabolic remodelingMLXIPL

Identifiers

PMID42064763
PMCPMC13125001

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.